(Q33404602)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

title

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

main subject

cytotoxicity

0 references

dasatinib monohydrate

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Satu Mustjoki

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Anna Kreutzman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Mathieu Molimard

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Kimmo Porkka

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

author name string

K Auvinen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

P Rousselot

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

S Hernesniemi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

T Melo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

A-M Lahesmaa-Korpinen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

S Bouchet

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

R Smykla

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

F Y Lee

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

J Vakkila

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

S Jalkanen

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

M Salmi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

publication date

29 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

page(s)

914-924

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2012.348

19 February 2020

exact match

0 references

cites work

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

CLEVER-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Lck is a key target of imatinib and dasatinib in T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Comprehensive analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Mechanisms and functions of Eph and ephrin signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

EphA and ephrin-A proteins regulate integrin-mediated T lymphocyte interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Latent cytomegalovirus infection amplifies CD8 T-lymphocyte mobilisation and egress in response to exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Selective mobilization of cytotoxic leukocytes by epinephrine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

c-Src tyrosine kinase binds the beta 2-adrenergic receptor via phospho-Tyr-350, phosphorylates G-protein-linked receptor kinase 2, and mediates agonist-induced receptor desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

inferred from DOI database lookup

7 January 2021

based on heuristic

Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.348

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2012.348

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

19 February 2020

1014327975

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23192016%20AND%20SRC:MED&resulttype=core&format=json